1
|
Limoges MA, Lortie A, Demontier É, Quenum AJI, Lessard F, Drouin Z, Carrier N, Nguimbus LM, Beaulieu MC, Boire G, Piché A, Allard-Chamard H, Ramanathan S, Roux S. SARS-CoV-2 mRNA vaccine-induced immune responses in rheumatoid arthritis. J Leukoc Biol 2023; 114:358-367. [PMID: 37478373 PMCID: PMC10533224 DOI: 10.1093/jleuko/qiad086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 07/15/2023] [Accepted: 07/19/2023] [Indexed: 07/23/2023] Open
Abstract
Our objective was to characterize T and B cell responses to vaccination with SARS-CoV-2 antigens in immunocompromised rheumatoid arthritis (RA) patients. In 22 RA patients, clinical and biological variables were analyzed before and 4 weeks after each of 3 messenger RNA (mRNA) vaccine doses and compared with unmatched healthy individuals. Sequentially sampled peripheral blood mononuclear cells and sera were collected to determine immune profiles and to analyze the T cell response to a spike peptide pool and B cell specificity to the receptor-binding domain (RBD). Anti-spike antibodies were detectable in 6 of 22 RA patients after 1 dose of vaccine with increasing titers after each booster dose, although the overall response was lower compared with that in healthy control individuals. Responding patients after the first dose were more likely to have RA antibodies and a higher baseline proportion of circulating follicular B cells. In RA patients, the mRNA vaccine elicited a robust CD4+ T response to a spike peptide pool following the first and second doses. Consistent with the serologies, RBD-specific B cells exhibited a modest increase after the first dose and the second dose resulted in marked increases only in a fraction of the RA patients to both ancestral and omicron RBD. Our results highlight the importance of multidose COVID-19 vaccination in RA patients to develop a protective humoral response. However, these patients rapidly develop specific T CD4+ responses, despite delayed B cell responses.
Collapse
Affiliation(s)
- Marc-André Limoges
- Department of Immunology and Cell Biology, Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4
| | - Audrey Lortie
- Division of Rheumatology, Department of Medicine, Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4
| | - Élodie Demontier
- Division of Rheumatology, Department of Medicine, Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4
| | - Akouavi Julite Irmine Quenum
- Department of Immunology and Cell Biology, Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4
| | - Félix Lessard
- Division of Rheumatology, Department of Medicine, Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4
| | - Zacharie Drouin
- Division of Rheumatology, Department of Medicine, Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4
| | - Nathalie Carrier
- Division of Rheumatology, Department of Medicine, Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4
| | - Leopold Mbous Nguimbus
- Division of Rheumatology, Department of Medicine, Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4
| | - Marie-Claude Beaulieu
- Department of Family and Emergency Medicine, Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4
| | - Gilles Boire
- Division of Rheumatology, Department of Medicine, Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4
| | - Alain Piché
- Division of Infectious Diseases, Department of Medicine, Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4
- Department of Microbiology and Infectious Diseases, Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4
| | - Hugues Allard-Chamard
- Division of Rheumatology, Department of Medicine, Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4
| | - Sheela Ramanathan
- Department of Immunology and Cell Biology, Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4
| | - Sophie Roux
- Division of Rheumatology, Department of Medicine, Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4
| |
Collapse
|